Karyopharm Therapeutics Inc. (KPTI) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of XPOVIO (selinexor), a Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of cancer. The company operates as a single segment. As of October 30, 2025, there were 17,050,876 shares of Common Stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $44.0 million | $38.8 million | $112.0 million | $114.7 million |
| Net Loss | $(33.1) million | $(32.1) million | $(93.8) million | $(45.6) million |
| Loss Per Share (Diluted) | $(3.82) | $(3.85) | $(10.93) | $(10.40) |
| Cash & Investments | $45.9 million | $108.7 million | $45.9 million | $108.7 million |
| Total Debt (Principal) | $239.5 million | $239.5 million | $239.5 million | $239.5 million |
| Accumulated Deficit | $(1.66) billion | $(1.53) billion | $(1.66) billion | $(1.53) billion |
Note: Total Debt includes $24.5M in 2025 Notes, $100.0M in Senior Secured Term Loan, and $116.0M in 2029 Notes. Liquidity (Cash, Cash Equivalents, and Investments) decreased significantly from $108.7M at year-end 2024 to $45.9M at Q3 2025.
Material Changes vs. Prior Period
- Revenue: Q3 2025 total revenue increased 14% year-over-year to $44.0 million, driven by a 30% increase in license and other revenue ($12.0M vs $9.3M). Product revenue increased 9% to $32.0M. However, YTD revenue decreased 2% to $112.0M due to higher gross-to-net provisions (rebates and returns) in the first half of the year.
- Operating Expenses: Total operating expenses decreased 9% in Q3 2025 to $59.3 million, primarily due to cost reduction initiatives including a 20% workforce reduction announced in July 2025. R&D expenses dropped 15% to $30.5 million, and SG&A dropped 4% to $26.6 million.
- Net Loss: The YTD net loss more than doubled to $93.8 million compared to $45.6 million in the prior year. This increase is largely attributable to a $44.7 million non-cash gain on debt extinguishment recognized in Q2 2024 which did not recur in 2025, alongside higher interest expenses from new debt instruments issued in May 2024.
- Liquidity: Cash and investments declined by approximately $62.8 million from December 31, 2024, to September 30, 2025, due to operating cash burn and investment maturities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern within one year of the report date. This is due to significant accumulated deficits, recurring operating losses, and debt service obligations. The company expects current resources to fund operations into the second quarter of 2026.
- Subsequent Financing (October 2025): Following the quarter-end, the company executed a series of "Financing Transactions" to address liquidity:
- Issued $15.0M in new 2028 Convertible Notes.
- Exchanged $24.3M of 2025 Notes and $15.0M of 2029 Notes for common stock and warrants.
- Completed a private placement raising ~$8.8 million.
- Amended the Term Loan to increase the facility to $112.5 million and temporarily reduced the minimum liquidity covenant.
- Clinical Outlook: The company expects top-line data from the Phase 3 SENTRY trial (myelofibrosis) in March 2026 and the Phase 3 XPORT-EC-042 trial (endometrial cancer) in mid-2026.
- Risks: Key risks include the inability to raise additional capital, failure of ongoing clinical trials, regulatory challenges (including FDA shutdown impacts), and the potential for delisting from Nasdaq if the stock price remains below $1.00 (though a 1-for-15 reverse split was executed in February 2025 to regain compliance).
Investor Verification Checklist
- Cash Runway: Verify the post-financing cash balance and the specific terms of the October 2025 debt amendments to confirm the runway extends beyond Q2 2026.
- Debt Covenants: Review the amended minimum liquidity covenants ($10M temporary floor vs. $25M standard) and the interest payment-in-kind (PIK) provisions for the Term Loan and Convertible Notes.
- Revenue Quality: Analyze the gross-to-net provisions for XPOVIO, specifically the impact of the product return reserve increase noted in Q1 2025.
- Dilution Impact: Assess the total dilution from the October 2025 financing, including the issuance of ~5.7 million shares and ~4.6 million warrants to settle debt and fees.
- Clinical Milestones: Monitor the timeline for the SENTRY and XPORT-EC-042 trial data readouts, as these are critical for future valuation and potential strategic alternatives.